Chymotrypsin c mutations in chronic pancreatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 8, 2011, Pages 1238-1246

  Zhou, Jiayi ^a   Sahin Tóth, Miklós ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Chronic pancreatitis; Chymotrypsin C; Mutation; Trypsin

Indexed keywords

CARBOXYPEPTIDASE; CHYMOTRYPSIN; CHYMOTRYPSIN C; PROCARBOXYPEPTIDASE A1; PROCARBOXYPEPTIDASE A2; PROTEIN; SPINK1 PROTEIN; TRYPSIN; TRYPSINOGEN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALCOHOLISM; AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CHRONIC PANCREATITIS; COPY NUMBER VARIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME REGULATION; EXON; FAMILY HISTORY; FRANCE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMAN DEMOCRATIC REPUBLIC; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERPARATHYROIDISM; IDIOPATHIC DISEASE; INTRON; LOSS OF FUNCTION MUTATION; MOLECULAR MECHANICS; MOLECULAR MODEL; PANCREAS SECRETION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; TAIWAN; TROPICAL DISEASE;

EID: 79960471681     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06791.x     Document Type: Article

References (70)

1. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N. Engl. J. Med. 1995; 332: 1482-90.
2. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120: 682-707.
3. Witt H, Apte MV, Keim V, Wilson JS. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007; 132: 1557-73.
4. Yadav D, Slivka A, Sherman S etal. Smoking is underrecognized as a risk factor for chronic pancreatitis. Pancreatology 2010; 10: 713-19.
5. Andriulli A, Botteri E, Almasio PL, Vantini I, Uomo G, Maisonneuve P, ad hoc Committee of the Italian Association for the Study of the Pancreas. Smoking as a cofactor for causation of chronic pancreatitis: a meta-analysis. Pancreas 2010; 39: 1205-10.
6. Coté GA, Yadav D, Slivka A etal. North American Pancreatitis Study Group. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin. Gastroenterol. Hepatol. 2011; 9: 266-73.
7. Howes N, Lerch MM, Greenhalf W etal. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol. 2004; 2: 252-61.
8. Keim V, Bauer N, Teich N, Simon P, Lerch MM, Mössner J. Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene. Am. J. Med. 2001; 111: 622-6.
9. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952; 21: 54-63.
10. Le Bodic L, Bignon JD, Raguenes O etal. The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum. Mol. Genet. 1996; 5: 549-54.
11. Pandya A, Blanton SH, Landa B etal. Linkage studies in a large kindred with hereditary pancreatitis confirms mapping of the gene to a 16-cM region on 7q. Genomics 1996; 38: 227-30.
12. Whitcomb DC, Preston RA, Aston CE etal. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996; 110: 1975-80.
13. Whitcomb DC, Gorry MC, Preston RA etal. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat. Genet. 1996; 14: 141-5.
14. Teich N, Rosendahl J, Tóth M, Mössner J, Sahin-Tóth M. Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum. Mutat. 2006; 27: 721-30.
15. Szmola R, Sahin-Tóth M. Uncertainties in the classification of human cationic trypsinogen (PRSS1) variants as hereditary pancreatitis-associated mutations. J. Med. Genet. 2010; 47: 348-50.
16. Le Maréchal C, Masson E, Chen JM etal. Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat. Genet. 2006; 38: 1372-4.
17. Masson E, Le Maréchal C, Chandak GR etal. Trypsinogen copy number mutations in patients with idiopathic chronic pancreatitis. Clin. Gastroenterol. Hepatol. 2008; 6: 82-8.
18. Chen JM, Mercier B, Audrezet MP, Ferec C. Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J. Med. Genet. 2000; 37: 67-9.
19. Witt H, Luck W, Hennies HC etal. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat. Genet. 2000; 25: 213-16.
20. Pfutzer RH, Barmada MM, Brunskill AP etal. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119: 615-23.
21. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N. Engl. J. Med. 1998; 339: 653-8.
22. Sharer N, Schwarz M, Malone G etal. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 1998; 339: 645-52.
23. Witt H, Sahin-Tóth M, Landt O etal. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat. Genet. 2006; 38: 668-73.
24. Chen JM, Férec C. Chronic pancreatitis: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 2009; 10: 63-87.
25. Whitcomb DC. Genetic aspects of pancreatitis. Annu. Rev. Med. 2010; 61: 413-24.
26. Sahin-Tóth M. Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J. Biol. Chem. 2000; 275: 22750-5.
27. Sahin-Tóth M, Tóth M. Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem. Biophys. Res. Commun. 2000; 278: 286-9.
28. Szilágyi L, Kénesi E, Katona G, Kaslik G, Juhász G, Gráf L. Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J. Biol. Chem. 2001; 276: 24574-80.
29. Chen JM, Kukor Z, Le Maréchal C etal. Evolution of trypsinogen activation peptides. Mol. Biol. Evol. 2003; 20: 1767-77.
30. Kereszturi E, Sahin-Tóth M. Intracellular autoactivation of human cationic trypsinogen mutants causes reduced trypsinogen secretion and acinar cell death. J. Biol. Chem. 2009; 284: 33392-9.
31. Kume K, Masamune A, Kikuta K, Shimosegawa T. [-215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes exon 3 skipping and loss of the trypsin binding site. Gut. 2006; 55: 1214.
32. Király O, Boulling A, Witt H etal. Signal peptide variants that impair secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause autosomal dominant hereditary pancreatitis. Hum. Mutat. 2007; 28: 469-76.
33. Király O, Wartmann T, Sahin-Tóth M. Missense mutations in pancreatic secretory trypsin inhibitor (SPINK1) cause intracellular retention and degradation. Gut 2007; 56: 1433-8.
34. Boulling A, Le Maréchal C, Trouvé P, Raguénès O, Chen JM, Férec C. Functional analysis of pancreatitis-associated missense mutations in the pancreatic secretory trypsin inhibitor (SPINK1) gene. Eur. J. Hum. Genet. 2007; 15: 936-42.
35. Kereszturi E, Király O, Sahin-Tóth M. Minigene analysis of intronic variants in common SPINK1 haplotypes associated with chronic pancreatitis. Gut 2009; 58: 545-9.
36. Rosendahl J, Witt H, Szmola R etal. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat. Genet. 2008; 40: 78-82.
37. Masson E, Chen JM, Scotet V, Le Marechal C, Ferec C. Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. Hum. Genet. 2008; 123: 83-91.
38. Folk JE, Schirmer EW, Chymotrypsin CI. Isolation of the zymogen and the active enzyme: preliminary structure and specificity studies. J. Biol. Chem. 1965; 240: 181-92.
39. Folk JE, Cole PW, Chymotrypsin C II. Enzymatic specificity toward several polypeptides. J. Biol. Chem. 1965; 240: 193-7.
40. Iio-Akama K, Sasamoto H, Miyazawa K, Miura S, Tobita T. Active forms of chymotrypsin C isolated from autolyzed porcine pancreas glands. Biochim. Biophys. Acta 1985; 831: 249-56.
41. Brown JR, Cox DJ, Greenshields RN, Walsh KA, Yamasaki M, Neurath H. The chemical structure and enzymatic functions of bovine procarboxypeptidase A. Proc. Natl. Acad. Sci. U.S.A. 1961; 47: 1554-60.
42. Kerfelec B, Chapus C, Puigserver A. Existence of ternary complexes of procarboxypeptidase A in the pancreas of some ruminant species. Eur. J. Biochem. 1985; 151: 515-19.
43. Gomis-Rüth FX, Gómez M, Bode W, Huber R, Avilés FX. The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C. EMBO J. 1995; 14: 4387-94.
44. Keil-Dlouha V, Puigserver A, Marie A, Keil B. On subunit II of bovine procarboxypeptidase A. Enzymatic specificity after tryptic activation. Biochim. Biophys. Acta 1972; 276: 531-635.
45. Tomomura A, Fukushige T, Noda T, Noikura T, Saheki T. Serum calcium-decreasing factor (caldecrin) from porcine pancreas has proteolytic activity which has no clear connection with the calcium decrease. FEBS Lett. 1992; 301: 277-81.
46. Tomomura A, Tomomura M, Fukushige T etal. Molecular cloning and expression of serum calcium-decreasing factor (caldecrin). J. Biol. Chem. 1995; 270: 30315-21.
47. Tomomura A, Akiyama M, Itoh H etal. Molecular cloning and expression of human caldecrin. FEBS Lett. 1996; 386: 26-8.
48. Hasegawa H, Kido S, Tomomura M etal. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity. J. Biol. Chem. 2010; 285: 25448-57.
49. Nemoda Z, Sahin-Tóth M. Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen. J. Biol. Chem. 2006; 281: 11879-86.
50. Nemoda Z, Sahin-Tóth M. The tetra-aspartate motif in the activation peptide of human cationic trypsinogen is essential for autoactivation control but not for enteropeptidase recognition. J. Biol. Chem. 2005; 280: 29645-52.
51. Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology 1999; 117: 7-10.
52. Szmola R, Sahin-Tóth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 11227-32.
53. Borgström B, Dahlqvist A, Lundh G, Sjovall J. Studies of intestinal digestion and absorption in the human. Eur. J. Clin. Invest. 1957; 36: 1521-36.
54. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am. J. Physiol. 1986; 251: G475-80.
55. Bohe M, Borgström A, Genell S, Ohlsson K. Metabolism of 131I-labelled human pancreatic cationic trypsin after intraduodenal administration. Digestion 1986; 34: 127-35.
56. Bódi A, Kaslik G, Venekei I, Gráf L. Structural determinants of the half-life and cleavage site preference in the autolytic inactivation of chymotrypsin. Eur. J. Biochem. 2001; 268: 6238-46.
57. Kukor Z, Tóth M, Pál G, Sahin-Tóth M. Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. J. Biol. Chem. 2002; 277: 6111-17.
58. Bronner F. Mechanisms of intestinal calcium absorption. J. Cell. Biochem. 2003; 88: 387-93.
59. Duflos C, Bellaton C, Pansu D, Bronner F. Calcium solubility, intestinal sojourn time and paracellular permeability codetermine passive calcium absorption in rats. J. Nutr. 1995; 125: 2348-55.
60. Rinderknecht H. Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. Dig. Dis. Sci. 1986; 31: 314-21.
61. Rinderknecht H, Adham NF, Renner IG, Carmack C. A possible zymogen self-destruct mechanism preventing pancreatic autodigestion. Int. J. Pancreatol. 1988; 3: 33-44.
62. Whitcomb DC. The first international symposium on hereditary pancreatitis. Pancreas 1999; 18: 1-12.
63. Avilés FX, Vendrell J, Guasch A, Coll M, Huber R. Advances in metallo-procarboxypeptidases. Emerging details on the inhibition mechanism and on the activation process. Eur. J. Biochem. 1993; 211: 381-9.
64. Szmola R, Bence M, Carpentieri A etal. Chymotrypsin C is a co-activator of human pancreatic procarboxypeptidases A1 and A2. J. Biol. Chem. 2011; 286: 1819-27.
65. Felderbauer P, Karakas E, Fendrich V, Lebert R, Bartsch DK, Bulut K. Multifactorial genesis of pancreatitis in primary hyperparathyroidism: evidence for "protective" (PRSS2) and "destructive" (CTRC) genetic factors. Exp. Clin. Endocrinol. Diabetes 2011; 119: 26-9.
66. Derikx MH, Szmola R, te Morsche RH, Sunderasan S, Chacko A, Drenth JP. Tropical calcific pancreatitis and its association with CTRC and SPINK1 (p.N34S) variants. Eur. J. Gastroenterol. Hepatol. 2009; 21: 889-94.
67. Chang MC, Chang YT, Wei SC etal. Association of novel chymotrypsin C gene variations and haplotypes in patients with chronic pancreatitis in Chinese in Taiwan. Pancreatology 2009; 9: 287-92.
68. Szmola R, Sahin-Tóth M. Pancreatitis-associated chymotrypsinogen C (CTRC) mutant elicits endoplasmic reticulum stress in pancreatic acinar cells. Gut 2010; 59: 365-72.
69. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007; 8: 519-29.
70. Kereszturi E, Szmola R, Kukor Z etal. Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a novel disease mechanism. Hum. Mutat. 2009; 30: 575-82.